Radiopharm Theranostics Seeks Approval for $18.5M Capital Raise
Radiopharm Theranostics Ltd will hold an Extraordinary General Meeting (EGM) on September 11, 2026, to seek shareholder approval for various aspects of its approximately $18.5 million capital raise. The resolutions include ratifying previously issued shares and approving the issuance of new shares, attaching options, and warrants to fund drug manufacturing, clinical trials, and working capital. The capital raise comprises a two-tranche placement, a Share Purchase Plan (SPP), and a US Direct Registration Offering.
Key Highlights
- EGM scheduled for September 11, 2026, to approve capital raise resolutions.
- Seeking shareholder approval for an approximately $18.5 million capital raise.
- Ratification of 408,839,531 First Tranche Placement Shares issued on August 3, 2026.
- Ratification of 384,493,800 ADS Shares from US offering issued on July 28, 2026.
- Approval for issuance of up to 40,000,000 Second Tranche Placement Shares.
- Approval for issuance of up to 448,839,531 Placement Attaching Options.
- Approval for issuance of up to 666,666,667 SPP Shares and 666,666,667 SPP Attaching Options.
- Funds from the capital raise will be used for drug manufacturing, clinical trials, and working capital.
Price Impact
More from RADX
Radiopharm Theranostics RAD101 Phase 3 Trial Set for 1Q27; RAD301 Data Positive
Radiopharm Theranostics Reports Positive RAD 101 Phase 2b Results; Raises $12.5M
Radiopharm RAD 101 Phase 2b Positive; 93% Met Endpoint; Raises $12.5M
More in Corporate Action